Is Grifols (BME:GRF) Pricing Reflect Recent Governance Concerns Or A Longer Term Opportunity?

• Wondering whether Grifols at around €9.16 a share is offering genuine value or just looks cheap on the surface? This article walks through what the current price might actually be telling you.
• The stock has returned 2.2% over the last week and 1.2% over the last month, while the year to date return sits at an 18.2% decline and the 1 year return is 13.3%, set against a 16.1% decline over 3 years and a 59.8% decline over 5 years.
• Recent headlines around Grifols have focused on its balance sheet, governance questions and responses from both the company and external reviewers, which have kept sentiment sensitive and contributed to share price swings. For you as a shareholder or potential investor, that backdrop makes it especially important to separate noise from what the numbers imply about value.
• On Simply Wall St's valuation framework Grifols scores 5 out of 6. This raises an obvious question about how different valuation methods, and one often overlooked approach at the end of this article, line up with that score.

Find out why Grifols's 13.3% return over the last year is lagging behind its peers.

Approach 1: Grifols Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and then discounting those back to today to reflect risk and the time value of money.

For Grifols, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow stands at about €657.2 million. Analyst estimates and Simply Wall St extrapolations project annual free cash flow rising to €1,618.0 million by 2030, with interim projections such as €542.2 million in 2026 and €1,014.5 million in 2028, all in euros and adjusted back to present value.

Discounting these projected cash flows results in an estimated intrinsic value of €25.64 per share. Compared with a current share price of around €9.16, the model implies a 64.3% discount, which points to the stock trading well below this DCF estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Grifols is undervalued by 64.3%. Track this in your watchlist or portfolio, or discover 229 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Grifols.

Approach 2: Grifols Price vs Earnings

For profitable companies like Grifols, the P/E ratio is a useful way to relate what you are paying for each share to the earnings that support that price. The higher the expected growth and the lower the perceived risk, the higher the P/E ratio investors are usually prepared to pay, and the opposite is also true.

Grifols currently trades on a P/E of 15.5x. That sits below the Biotechs industry average P/E of 27.7x and the peer group average of 30.3x, which suggests the stock is priced more cautiously than many peers based on earnings alone.

Simply Wall St also calculates a “Fair Ratio” of 34.2x for Grifols. This is a proprietary estimate of what the P/E might be, given factors such as earnings growth, industry, profit margin, market cap and specific risks. It can be more informative than a simple comparison with peers or the broad industry, because it adjusts for the company’s own characteristics rather than assuming all businesses deserve the same multiple.

Comparing the current 15.5x P/E to the 34.2x Fair Ratio suggests the stock is trading below this Fair Ratio based assessment.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 100 top founder-led companies.

Upgrade Your Decision Making: Choose your Grifols Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced as a simple way for you to write the story behind your numbers by linking your view on a company to assumptions for future revenue, earnings and margins, which then flow into an estimated fair value.

On Simply Wall St, Narratives sit in the Community page and give you an easy tool to connect a company story to a financial forecast, then compare the resulting Fair Value to the current share price to help decide whether you see the stock as priced attractively or expensively at any point in time.

Because Narratives on the platform are updated when fresh information like news, earnings or guidance arrives, your fair value view is not static, and you can quickly see how your story and numbers for Grifols stack up against those of other investors.

For example, one Grifols Narrative could look closer to the bullish view that supports a Fair Value around €21.72 and a higher future P/E. Another could line up with the cautious view that points to a Fair Value near €9.00. Comparing those to today’s price helps you decide which story you think is more reasonable.

For Grifols however, we will make it really easy for you with previews of two leading Grifols Narratives:

These are not predictions. They are structured stories that link specific business assumptions to an implied fair value so you can see which version of the future feels closer to your own view.

🐂 Grifols Bull Case

Fair value in this bullish narrative: €15.08

Implied discount to this fair value at a €9.16 share price: about 39%.

Revenue growth assumption: 5.63% a year.

• Analysts in this camp see steady revenue growth and margin expansion supported by demand for plasma therapies, a broadening product set and new markets.
• They weigh risks like pricing pressure, currency swings, reliance on plasma collection and high debt, but still view them as manageable within the thesis.
• The narrative lines up with a consensus price target of about €16.48, which is higher than the current share price, anchored on earnings of €893.1m and a future P/E of 17.2x by 2028.

🐻 Grifols Bear Case

Fair value in this bearish narrative: €9.00

Implied premium to this fair value at a €9.16 share price: about 2%.

Revenue growth assumption: 5.32% a year.

• This group is more focused on threats from gene therapies, synthetic biologics, tighter regulation and donor related cost pressures potentially weighing on long term demand and margins.
• They still assume revenue and profit margins improve from today, but pair those assumptions with a much lower future P/E of 10.5x and a slightly lower growth rate than the bullish view.
• The resulting fair value of €9.00 matches the lowest analyst target and implies the current market price already bakes in optimistic expectations, leaving less room for disappointment.

The key takeaway is that the same company, using reasonably close revenue and margin assumptions, can lead to very different conclusions once you layer in risk, required returns and the P/E you think is justified. Your job is to decide which story feels closer to your own expectations for Grifols and to price in a margin of safety that you are comfortable with.

If you want to see how other investors are joining the dots between growth, risks and valuation for this stock, take a look at the full range of Grifols Narratives on the Community page and use them as a reference point for your own work rather than a script to follow.

Do you think there's more to the story for Grifols? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com